Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Characterization of Primary Mediastinal Large B-Cell Lymphomas.
Donzel M, Pesce F, Trecourt A, Groussel R, Bachy E, Ghesquières H, Fontaine J, Benzerdjeb N, Mauduit C, Traverse-Glehen A. Donzel M, et al. Among authors: traverse glehen a. Cancers (Basel). 2023 Oct 6;15(19):4866. doi: 10.3390/cancers15194866. Cancers (Basel). 2023. PMID: 37835560 Free PMC article.
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.
Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A, Algara P, Santoro A, Gonzalez D, Mollejo M, Dagklis A, Gangemi F, Bosler DS, Bourikas G, Anagnostopoulos A, Tsaftaris A, Iannitto E, Ponzoni M, Felman P, Berger F, Belessi C, Ghia P, Papadaki T, Dogan A, Degano M, Matutes E, Piris MA, Oscier D, Stamatopoulos K. Bikos V, et al. Leukemia. 2012 Jul;26(7):1638-46. doi: 10.1038/leu.2012.3. Epub 2012 Jan 6. Leukemia. 2012. PMID: 22222599
An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.
Bikos V, Karypidou M, Stalika E, Baliakas P, Xochelli A, Sutton LA, Papadopoulos G, Agathangelidis A, Papadopoulou E, Davis Z, Algara P, Kanellis G, Traverse-Glehen A, Mollejo M, Anagnostopoulos A, Ponzoni M, Gonzalez D, Pospisilova S, Matutes E, Piris MA, Papadaki T, Ghia P, Rosenquist R, Oscier D, Darzentas N, Tzovaras D, Belessi C, Hadzidimitriou A, Stamatopoulos K. Bikos V, et al. Clin Cancer Res. 2016 Apr 15;22(8):2032-40. doi: 10.1158/1078-0432.CCR-15-1170. Epub 2015 Dec 8. Clin Cancer Res. 2016. PMID: 26647217
Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis.
Thieblemont C, Chettab K, Felman P, Callet-Bauchu E, Traverse-Glehen A, Berger F, Dumontet C, Cerutti C, Baseggio L, Salles G, Paultre C, Coiffier B, McGregor JL. Thieblemont C, et al. Leukemia. 2002 Nov;16(11):2326-9. doi: 10.1038/sj.leu.2402691. Leukemia. 2002. PMID: 12399979 No abstract available.
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. Engert A, et al. Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27. Haematologica. 2016. PMID: 26819058 Free PMC article.
Selection of antigen receptors in splenic marginal-zone lymphoma: further support from the analysis of the immunoglobulin light-chain gene repertoire.
Bikos V, Stalika E, Baliakas P, Darzentas N, Davis Z, Traverse-Glehen A, Dagklis A, Kanellis G, Anagnostopoulos A, Tsaftaris A, Ponzoni M, Berger F, Felman P, Ghia P, Papadaki T, Oscier D, Belessi C, Stamatopoulos K. Bikos V, et al. Leukemia. 2012 Dec;26(12):2567-9. doi: 10.1038/leu.2012.207. Epub 2012 Jun 18. Leukemia. 2012. PMID: 22858907 No abstract available.
Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survival.
Thieblemont C, Rolland D, Baseggio L, Felman P, Gazzo S, Callet-Bauchu E, Traverse-Glehen A, Houlgatte R, Fu K, Weisenburger D, De Jong D, Jaffe ES, Rosenwald A, Ott G, Coiffier B, Berger F. Thieblemont C, et al. Leuk Lymphoma. 2008 Jul;49(7):1403-6. doi: 10.1080/10428190802094245. Leuk Lymphoma. 2008. PMID: 18604726 Free PMC article. No abstract available.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
160 results